Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer

Apoptosis

Volumn 15, Issue 8, 2010, Pages 956-965

  Carvalho, João R ^a   Filipe, Luísa ^a   Costa, Vera L ^a   Ribeiro, Franclim Ricardo ^a   Martins, Ana T ^a   Teixeira, Manuel R ^a,b   Jerónimo, Carmen ^a   Henrique, Rui ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Apoptosis; Promoter methylation; Prostate cancer; Prostatic intraepithelial neoplasia; Quantitative MSP; Quantitative RT PCR

Indexed keywords

CASPASE 3; CASPASE 8; DEATH ASSOCIATED PROTEIN KINASE; DEATH RECEPTOR 3; DEATH RECEPTOR 4; FAS ANTIGEN; MESSENGER RNA; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RNA METHYLATION; TUMOR GENE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROMOTER REGION; PROSTATE TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 77956905086     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-010-0508-6     Document Type: Article

References (45)

1. Bremer E, van Dam G, Kroesen BJ, de Leij L, Helfrich W (2006) Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol Med 12:382-393
2. Ashkenazi A (2008) Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7:1001-1012
3. Hector S, Prehn JH (2009) Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: a review. Biochim Biophys Acta 1795:117-129
4. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
6. Nelson WG, De Marzo AM, Isaacs WB (2003) Prostate cancer. N Engl J Med 349:366-381
7. Zhang XK (2002) Vitamin A and apoptosis in prostate cancer. Endocr Relat Cancer 9:87-102
8. Murphy TM, Perry AS, Lawler M (2008) The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer. Endocr Relat Cancer 15:11-25
9. Friedrich MG, Weisenberger DJ, Cheng JC et al (2004) Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 10:7457-7465
10. Costa VL, Henrique R, Jeronimo C (2007) Epigenetic markers for molecular detection of prostate cancer. Dis Markers 23:31-41
11. Jeronimo C, Henrique R, Hoque MO et al (2004) A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 10:8472-8478
12. Wittekind CF, Greene FL, Hutter RVP, Klimpfinger M, Sobin LH (2005) Prostate. In: Wittekind CF, Greene FL, Hutter RVP, Klimpfinger M, Sobin LH (eds) TNM atlas: illustrated guide to the TNM/pTNM classification of malignant tumours, 5th edn. Springer, Berlin, pp 283-291
13. Henrique R, Jeronimo C, Hoque MO et al (2005) MT1G hyper-methylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev 14:1274-1278
14. Eads CA, Danenberg KD, Kawakami K et al (2000) MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28:E32
15. Petak I, Danam RP, Tillman DM et al (2003) Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death Differ 10:211-217
16. Hopkins-Donaldson S, Ziegler A, Kurtz S et al (2003) Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 10:356-364
17. de Miguel MP, Royuela M, Bethencourt FR, Santamaria L, Fraile B, Paniagua R (2000) Immunoexpression of tumour necrosis factor-alpha and its receptors 1 and 2 correlates with prolifera-tion/apoptosis equilibrium in normal, hyperplasic and carcino-matous human prostate. Cytokine 12:535-538
18. Hesry V, Piquet-Pellorce C, Travert M et al (2006) Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Prostate 66: 987-995
19. O'Neill AJ, Boran SA, O'Keane C et al (2001) Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma. Prostate 47:183-188
20. Gopisetty G, Ramachandran K, Singal R (2006) DNA methyla-tion and apoptosis. Mol Immunol 43:1729-1740
21. Lehmann U, Celikkaya G, Hasemeier B, Langer F, Kreipe H (2002) Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res 62:6634-6638
22. Yegnasubramanian S, Kowalski J, Gonzalgo ML et al (2004) Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64:1975-1986
23. Maruyama R, Toyooka S, Toyooka KO et al (2002) Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 8:514-519
24. Zuzak TJ, Steinhoff DF, Sutton LN, Phillips PC, Eggert A, Grotzer MA (2002) Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/ medulloblastoma. Eur J Cancer 38:83-91
25. Shivapurkar N, Toyooka S, Eby MT et al (2002) Differential inac-tivation of caspase-8 in lung cancers. Cancer Biol Ther 1:65-69
26. Kim HS, Lee JW, Soung YH et al (2003) Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology 125:708-715
27. Barbero S, Mielgo A, Torres V et al (2009) Caspase-8 association with the focal adhesion complex promotes tumor cell migration and metastasis. Cancer Res 69:3755-3763
28. Collard RL, Harya NS, Monzon FA, Maier CE, O'Keefe DS (2006) Methylation of the ASC gene promoter is associated with aggressive prostate cancer. Prostate 66:687-695
29. Das PM, Ramachandran K, Vanwert J et al (2006) Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol Cancer 5:28
30. Suzuki M, Shigematsu H, Shivapurkar N et al (2006) Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer. Cancer Lett 242:222-230
31. Masumoto J, Dowds TA, Schaner P et al (2003) ASC is an activating adaptor for NF-kappa B and caspase-8-dependent apoptosis. Biochem Biophys Res Commun 303:69-73
32. Krajewska M, Krajewski S, Epstein JI et al (1996) Immunohis-tochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148:1567-1576
33. Colombel M, Symmans F, Gil S et al (1993) Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 143:390-400
34. Mackler NJ, Pienta KJ (2005) Drug insight: use of docetaxel in prostate and urothelial cancers. Nat Clin Pract Urol 2:92-100
35. Yoshino T, Shiina H, Urakami S et al (2006) Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 12:6116-6124
36. Kyprianou N, King ED, Bradbury D, Rhee JG (1997) bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 70:341-348
37. Cho NY, Kim BH, Choi M et al (2007) Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopatho-logical features. J Pathol 211:269-277
38. Catz SD, Johnson JL (2001) Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20:7342-7351
39. Vinci S, Giannarini G, Selli C, et al. (2009) Quantitative meth-ylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of non-muscle-invasive urothelial carcinoma of the bladder: a prospective, two-center validation study. Urol Oncol. doi:10.1016/j.urolonc.2009.01.003
40. Kang GH, Lee S, Cho NY et al (2008) DNA methylation profiles of gastric carcinoma characterized by quantitative DNA meth-ylation analysis. Lab Invest 88:161-170
41. Santourlidis S, Warskulat U, Florl AR et al (2001) Hyperme-thylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma. Mol Carcinog 32:36-43
42. Betel D, Wilson M, Gabow A, Marks DS, Sander C (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res 36:D149-D153
43. O'Kane HF, Watson CJ, Johnston SR, Petak I, Watson RW, Williamson KE (2006) Targeting death receptors in bladder, prostate and renal cancer. J Urol 175:432-438
44. Lee SH, Shin MS, Park WS et al (1999) Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res 59:3068-3072
45. Takayama H, Takakuwa T, Dong Z et al (2001) Fas gene mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of laser capture microdissected specimens. Lab Invest 81:283-288